BioCardia, Inc. 8-K

What Happened On June 5, 2026, BioCardia, Inc. issued a press release and filed a Form 8-K (Item 7.01) disclosing that it received minutes from a Q‑Sub meeting with the FDA’s Center for Biologics Evaluation and Research (CBER) regarding the CardiAMP Cell Therapy System. The FDA minutes confirm that the ongoing CardiAMP Heart Failure II Trial may be used to support a Premarket Approval (PMA) submission for treatment of ischemic heart failure with reduced ejection fraction (HFrEF). The press release is attached as Exhibit 99.1 to the 8‑K.

Key Details

• Date filed: June 5, 2026 (Form 8‑K, Item 7.01; Exhibit 99.1 press release).
• Agency: FDA Center for Biologics Evaluation and Research (CBER) Q‑Sub meeting minutes received.
• Program/Trial: CardiAMP Cell Therapy System; ongoing CardiAMP Heart Failure II Trial.
• Regulatory implication: FDA minutes state the ongoing trial may be used to support a PMA for ischemic HFrEF.

Why It Matters This disclosure is a regulatory development: the FDA’s acknowledgment that the ongoing pivotal trial can support a PMA is a positive procedural milestone toward potential market clearance for CardiAMP if the trial and submission meet FDA requirements. For investors, it reduces some regulatory uncertainty around the pathway to approval, but it is not an approval and does not change clinical or financial results by itself. The 8‑K contains no new financial data—only the company’s public regulatory update.